Allergan announces new $2B share repurchase plan, affirms guidance
Allergan announced that the company's Board of Directors has authorized a new $2B share repurchase program, and has affirmed its commitment to increasing its regular quarterly cash dividend annually for shareholders as part of the company's capital allocation strategy. As part of its commitment to maintaining investment grade credit ratings, the company also reaffirms its commitment to pay down $3.75M of debt in 2018. These actions reflect the Company's conviction in its business strategy and strong future cash flow position, allowing for periodic return of cash to shareholders through dividends and share buybacks while maintaining investment grade ratings and continuing its debt pay down strategy. In reaffirming its 2017 financial guidance issued on August 3, 2017 the company also affirmed third quarter revenue projections.